Key Highlights

  • Net loss was USD 6.5 million versus USD 7.5 million a year earlier.
  • Research and development expense fell to USD 3.7 million from USD 4.0 million.
  • Cash stood at USD 8.3 million against an accumulated Deficit of USD 297.6 million.
  • Nine-month operating cash use was USD 19.1 million.

Net Loss Narrows Before a Deemed Dividend

Aptevo Therapeutics Inc. (NASDAQ:APVO) reported a third-quarter net loss of USD 6,549 thousand versus USD 7,549 thousand a year earlier. A deemed Dividend of USD 2,798 thousand, versus USD 1,479 thousand, brought the net loss attributable to common stockholders to USD 9,347 thousand versus USD 9,028 thousand. The data set lists an estimated loss of USD 3.72 per share and no actual figure.

Research and development expenses decreased USD 0.3 million to USD 3.7 million from USD 4.0 million, which the filing attributes to lower supply, laboratory and consulting costs.

Nine-Month Results

For the nine months, net loss was USD 19.6 million versus USD 20.2 million, and net loss attributable to common stockholders was USD 22.5 million, after a deemed dividend of USD 2.9 million. Net cash used in Operating Activities was USD 19.1 million, and the filing reports an accumulated deficit of USD 297.6 million at September 30, 2026.

The deemed dividend was USD 2.9 million for the nine months versus USD 1.5 million a year earlier, and other income, net, was USD 292 thousand versus USD 155 thousand. Quarterly other income, net, was USD 65 thousand versus USD 61 thousand.

Company Profile and Funding Disclosure

The company is a "clinical-stage, Research and Development biotechnology company focused on developing novel immunotherapy candidates" for different forms of cancer, built on two platform technologies for designing precision immune modulatory drugs, with two clinical candidates.

Cash and cash equivalents were USD 8.3 million. The filing states that management and the board have concluded that substantial doubt exists about the company's ability to continue as a going concern, and it lists recurring losses from operations among the reasons.

The filing adds that the company has suffered recurring losses from operations and lists that history among the conditions behind its Going Concern conclusion. Net cash used in operating activities for the nine months was USD 19.1 million, and the accumulated deficit of USD 297.6 million compares with cash and cash equivalents of USD 8.3 million, so the Balance Sheet carries limited Liquidity against the current rate of spending. Quarterly net loss attributable to common stockholders includes the USD 2.8 million deemed dividend recorded under Note 8.

What Investors Are Watching

Reference points include clinical progress for the two candidates, quarterly research spending near USD 3.7 million, the effect of deemed dividends on the per-share loss and any new financing set out in the liquidity discussion.

The deemed dividend, the going concern statement and the USD 8.3 million cash balance are the figures the filing places side by side.